SCHEMBL91472

SCHEMBL91472

Cc1ccnc(NCC(F)(F)F)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 1/20 0.46
CDK2 P24941 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
MAPT P10636 1/20 0.42
CYP2C9 P11712 1/20 0.42
IDH2 P48735 1/20 0.40
SORT1 Q99523 1/20 0.40
MAPK1 P28482 1/20 0.40
NPC1 O15118 3/20 0.40
PKM P14618 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
TP53 P04637 2/20 0.40
HRH4 Q9H3N8 3/20 0.39
HRH3 Q9Y5N1 2/20 0.39
ALDH1A1 P00352 1/20 0.39
FASN P49327 1/20 0.38
LMNA P02545 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17700502 0.86 NPSR1 (0.42) NPSR1MAPTCYP2C9SORT1MAPK1
SCHEMBL14029983 0.84 HRH4 (0.54) NPSR1MAPTCYP2C9MAPK1HRH4
SCHEMBL84099 0.78 CDK4 (0.43) CDK4CDK2IDH2HRH4HRH3
SCHEMBL91473 0.77 NPSR1 (0.49) NPSR1MAPTCYP2C9MAPK1NPC1
SCHEMBL17700480 0.77 KMT2A (0.50) MAPTMAPK1NPC1RAB9ASMN1; SMN2
SCHEMBL10224745 0.76 CRHR1 (0.49) MAPTSORT1TP53
SCHEMBL17700283 0.75 NPSR1 (0.44) NPSR1MAPTCYP2C9MAPK1NPC1
SCHEMBL17700115 0.74 ALDH1A1 (0.54) CDK4CDK2ALDH1A1
SCHEMBL91452 0.74 NPSR1 (0.46) NPSR1MAPTCYP2C9MAPK1NPC1
SCHEMBL30299494 0.73 CDK4 (0.54) CDK4CDK2MAPTTP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3031799-B1 AROMATIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-04-04 EP disclosed
US-9776962-B2 Aromatic compounds with GPR40 agonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-10-03 US disclosed
EP-3031799-A1 AROMATIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-15 EP disclosed
US-20160115128-A1 AROMATIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-04-28 US disclosed
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160115128-A1 AROMATIC COMPOUND GLP1R, GPR119, GPR39 CDK4 2846/4885CDK2 4440/4885NPSR1 1354/4885
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS CDK4 12/4885CDK2 20/4885NPSR1 4364/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS CDK4 20/4885CDK2 34/4885NPSR1 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.